Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention

Table 2

Outcomes with dual therapy compared with triple therapy after PCI.

Study/author	MACE (%)	Mortality (%)	Stent thrombosis (%)	Total bleeding (%)	Major bleeding (%)
RE-DUAL PCI [31]	NR	4.9/5.6; 4.6/3.9	0.8/1.5 [0.15]; 0.9/0.9 [0.98]	42.9/27.1 [<0.001]; 41.4/33.3 [<0.001]	9.2/5.0 [<0.001]; 8.4/5.6 [0.02]
De Vecchis et al. [33]	27.1/12.9 [0.32]	8.3/0 [0.26]	2/0 [0.59]	16.7/19.4 [0.90]	8.3/6.5 [0.89]
PIONEER [12]	6.0/6.5 [0.75]	1.9/2.4 [0.52]	0.7/0.8 [0.79]	26.7/16.8 [<0.01]	3.3/2.1 [0.23]
ORBIT-AF [34]	NR	4.1/5.4 [0.57]	NR	NR	5.68/5.85 [0.66]
AFCAS [24]	22/18 [0.72]	11/7 [0.54]	1/3 [0.60]	18/16 [0.66]	10/7 [0.43]
WARSTENT [25]	16/15 [0.98]	5/0 [0.45]	1/0 [0.76]	11/5 [0.34]	4/5 [0.84]
Braun et al. [35]	NR	3.2/3.8 [NS]	0/0 [NS]	NR	7/7.5 [NS]
Lamberts et al. [36]	NR	8.9/7.1 [NS]	NR	14.3/10.9 [NS]	0.9/0.5 [NS]
WOEST [9]	NR	6.3/3.5 [0.03]	3.2/1.4 [0.17]	44.4/19.4 [<0.01]	5.6/3.2 [0.16]
Rubboli et al. [37]	32/24.6 [0.19]	9.9/10.2 [0.78]	2.7/2.0 [0.77]	NR	5.0/2.6 [0.32]
Persson et al. [38]	NR	3.0/4.2 [0.43]	NR	4.7/1.3 [0.02]	2.7/0.3 [0.03]
Gao et al. [39]	8.8/14.9 [0.01]	4.4/5.8 [0.17]	0.7/1.7 [0.73]	11.8/7.4 [0.038]	2.9/2.5 [0.73]
MUSICA [40]	23.7/26.1 [0.001]	6.8/10.9 [0.06]	4.0/8.7 [0.04]	15.5/13 [0.02]	4.3/6.5 [0.29]
Sørensen et al. [41]	NR	[NS]	NR	3.2/1.6 [NS]	NR
GRACE [26]	NR	5.1/6.5 [0.47]	NR	NR	5.9/4.6 [0.46]
Karjalainen et al. [42]	21.9/11 [0.003]	8.7/1.8 [0.003]	4.1/1.3 [0.09]	NR	8.2/2.6 [0.01]

NR = not reported; NS = statistically nonsignificant; number preceding “/” denotes TT (triple therapy) and number proceeding “/” denotes DT (dual therapy), TT/DT; for RE-DUAL PCI: = Therapy with Dabigatran 110 mg BID; = Therapy with Dabigatran 150 mg BID.